新闻源 财富源

2019年10月20日 星期天

康缘药业(600557)公告正文

康缘药业:2011年第三季度报告

公告日期:2011-10-25

股票简称:康缘药业                                  股票代码:600557




              江苏康缘药业股份有限公司


                     2011 年第三季度报告




                      二〇一一 年 十 月 二十三 日
      江苏康缘药业股份有限公司(股票代码:600557)                    2011 年第三季度报告




                                            目 录

§1 重要提示.......................................................................... 2
§2 公司基本情况 ...................................................................... 2
§3 重要事项.......................................................................... 3
§4 附录.............................................................................. 7




                                                 1
      江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



§1 重要提示
    1.1 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假
记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。

    1.2 公司全体董事出席董事会会议。

    1.3 公司第三季度财务报告未经审计。

    1.4

 公司负责人姓名                                                           肖 伟
 主管会计工作负责人姓名                                                   陈友龙
 会计机构负责人(会计主管人员)姓名                                       焦晓杉
    公司负责人肖伟、主管会计工作负责人陈友龙及会计机构负责人(会计主管人员)焦晓杉声明:
保证本季度报告中财务报告的真实、完整。



§2 公司基本情况
    2.1 主要会计数据及财务指标
                                                                                     币种:人民币
                                                                 上年度期末      本报告期末比上年
                                             本报告期末
                                                              调整后    调整前     度期末增减(%)
总资产                                    2,461,545,702.78    1,987,481,196.13                23.85
所有者权益(或股东权益)                  1,408,920,594.51    1,209,173,803.04                16.52
归属于上市公司股东的每股净资产
                                                       3.33     2.86      2.91                   16.43
(元/股)
                                              年初至报告期期末(1-9 月)        比上年同期增减(%)
经营活动产生的现金流量净额(元)               -32,593,569.03   118,230,090.53               -127.57
每股经营活动产生的现金流量净额
                                                     -0.08      0.28      0.28              -128.57
(元/股)
                                                              年初至报告期期     本报告期比上年同
                                         报告期(7-9 月)
                                                              末(1-9 月)      期增减(%)(7-9 月)
归属于上市公司股东的净利润(元)                66,038,320.38     162,753,751.62                26.97
基本每股收益(元/股)                                  0.16               0.39                33.33
扣除非经常性损益后的基本每股收益
                                                      0.13               0.34                    8.33
(元/股)
稀释每股收益(元/股)                                 0.16               0.39                33.33
加权平均净资产收益率(%)                             5.32              12.69    增加 0.58 个百分点
扣除非经常性损益后的加权平均净资
                                                      4.26              11.33    减少 0.47 个百分点
产收益率(%)
    2011 年 6 月 17 日,公司实施 A 股限制性股票激励计划,首次授予 62 名激励对象共 7,600,000 股,
总股本由 415,646,691 股增加为 423,246,691 股。以上原因致使相关指标被相应摊薄。
    扣除非经常性损益项目和金额:
                                                                          单位:元 币种:人民币
                            项   目                             年初至报告期期末金额(1-9 月)
 非流动资产处置损益                                                                 505,760.13
 计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                                 20,412,050.08
 一标准定额或定量享受的政府补助除外)

                                                 2
      江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



 除上述各项之外的其他营业外收入和支出                                              178,187.81
 所得税影响额                                                                   -3,274,041.06
 少数股东权益影响额(税后)                                                       -395,094.12
                         合 计                                                  17,426,862.84

    2.2 报告期末股东总人数及前十名无限售条件股东持股情况表
                                                                                       单位:股
报告期末股东总数(户)                                                                       18,011
                              前十名无限售条件流通股股东持股情况
                                                              期末持有无限售条
                      股东名称(全称)                                                    种     类
                                                                件流通股的数量
连云港康贝尔医疗器械有限公司                                          22,132,338      人民币普通股
中国农业银行-长城安心回报混合型证券投资基金                          13,000,000      人民币普通股
肖伟                                                                  11,808,082      人民币普通股
招商银行股份有限公司-光大保德信优势配置股票型证券投资基金             9,234,388      人民币普通股
中国工商银行-中海能源策略混合型证券投资基金                           8,588,888      人民币普通股
中国工商银行股份有限公司-广发行业领先股票型证券投资基金               8,456,841      人民币普通股
中国平安人寿保险股份有限公司-传统-普通保险产品                       7,699,551      人民币普通股
中国太平洋人寿保险股份有限公司-传统-普通保险产品                     5,699,988      人民币普通股
中国建设银行-长城消费增值股票型证券投资基金                           5,610,523      人民币普通股
中国光大银行股份有限公司-国投瑞银景气行业证券投资基金                 5,172,544      人民币普通股


§3 重要事项
    3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因
    √适用 □不适用
    3.1.1 截至报告期末,公司资产负债项目大幅变动的原因分析
                                                                          单位:元 币种:人民币
     项    目           期末余额            年初余额        增减幅度             原因分析
                                                                        主要系年初至报告期期末公
交易性金融资产          1,000,000.00
                                                                        司购买银行理财产品所致
                                                                        主要系报告期内公司收到销
应收票据             388,677,966.58       259,445,585.48       49.81%
                                                                        售回款票据增加所致
                                                                        主要系报告期内公司加大市
                                                                        场推广力度,适当放宽经销
应收账款             687,815,633.91       457,703,102.01       50.28%
                                                                        商回款周期及金融环境影响
                                                                        所致
                                                                        主要系报告期内连云港康嘉
应收股利                3,607,284.00                                    国际贸易有限公司应付公司
                                                                        2010 年度分红款所致
                                                                        主要系年初至报告期期末公
长期股权投资            3,998,617.50                                    司参股北京健坤和医药科技
                                                                        有限公司所致
                                                                        主要系报告期内公司非募集
在建工程             181,729,700.86        99,901,320.99       81.91%
                                                                        资金项目投入增加所致
                                                                        主要系报告期内子公司摊销
长期待摊费用              112,954.28           571,754.28     -80.24%
                                                                        长期待摊费用所致
                                                                        主要系报告期内公司短期贷
短期借款             505,000,000.00       310,089,895.30       62.86%
                                                                        款增加所致

                                                 3
         江苏康缘药业股份有限公司(股票代码:600557)                                 2011 年第三季度报告



                                                                                  主要系报告期内公司销售收
应交税费                 42,451,572.19        28,849,214.47             47.15%
                                                                                  入增长,利润增加所致
                                                                                  主要系报告期内公司银行借
应付利息                   1,165,850.66              707,545.90         64.77%
                                                                                  款增加以及利率上浮所致
                                                                                  主要系报告期内江苏南星药
应付股利                   1,015,587.53                                           业有限公司尚未支付的 2010
                                                                                  年度分红款所致
                                                                                  主要系报告期内公司长期贷
长期借款                118,000,000.00        58,000,000.00          103.45%
                                                                                  款增加所致

    3.1.2 年初至报告期期末,公司利润表项目大幅动变动的原因分析
                                                                                    单位:元 币种:人民币
                   年初至报告期期      上年年初至报告
    项     目                                               增减幅度                       原因分析
                       末金额            期期末金额
                                                                         主要系年初至报告期期末公司银行
 财务费用            25,799,153.34       11,545,546.29        123.46%
                                                                         借款增加以及利率上浮所致
                                                                         主要系年初至报告期期末江苏南星
 投资收益               618,264.36        1,231,741.53        -49.81%    药业有限公司为公司控股子公司,核
                                                                         算方式由权益法变为成本法所致
                                                                         主要系年初至报告期期末公司获得
 营业外收入          20,772,518.52        9,995,181.00        107.83%
                                                                         政府补助同比增加所致
                                                                         主要系年初至报告期期末公司处置
 营业外支出             296,167.36          116,505.29        154.21%
                                                                         固定资产损失所致

    3.1.3 年初至报告期期末,公司现金流量表项目大幅动变动的原因分析
                                                                                    单位:元 币种:人民币
                        年初至报告期期       上年年初至报告
      项     目                                                    增减幅度                   原因分析
                            末金额             期期末金额
                                                                                 主要系年初至报告期期末公司
 经营活动产生的
                         -32,593,569.03       118,230,090.53        -127.57%     购买商品、支付劳务及应收账
 现金流量净额
                                                                                 款同比增加所致
                                                                                 主要系年初至报告期期末公司
 筹资活动产生的
                         278,858,931.98       100,125,669.03         178.51%     贷款增加及收到激励对象限制
 现金流量净额
                                                                                 性股票认购资金所致
    3.2 重大事项进展情况及其影响和解决方案的分析说明
    √适用 □不适用
    3.2.1 募集资金项目进展情况
    1、募集资金基本情况

        公司于 2008 年 1 月公开增发 10,465,116 股 A 股股票,共计募集资金 296,999,992.08 元,
   扣除各项发行费用后,实际募集资金为 282,456,989.24 元,于 2008 年 1 月 16 日全部到位,
   并经南京立信永华会计师事务所有限公司宁信会字[2008]第 0008 号《验资报告》验证。截至 2011
   年 9 月 30 日,公司累计投入募集资金项目 22438.58 万元,募集资金期末余额为 5807.12 万元。


    2、募集资金实际使用情况

                                                                                  单位:万元 币种:人民币
                             是否变   募集资金拟投    募集资金实   是否符合                 产生收    是否符合
      承诺项目名称                                                             项目进度
                             更项目     入金额        际投入金额   计划进度                 益情况    预计收益
现代中药注射剂生产线技术       否         15188.00      16056.65       是        100.00%    6337.76       是


                                                       4
       江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



改造项目
散结镇痛胶囊产业化项目       否         6268.00        3092.79   否    49.34%                否
创新中药研究与(GLP)安全
                             否         8260.00        3289.14   否    39.82%                否
评价中心项目
          合 计              /         29716.00       22438.58   /      /          /          /

    募集资金项目进展情况说明
    1、现代中药注射剂生产线技术改造项目 2011 年 1-9 月收入 33552.43 万元,产生收益 6337.76
万元。散结镇痛胶囊产业化项目和创新中药研究与(GLP)安全评价中心项目未完工,获得利息收入
19.49 万元。
    2、散结镇痛胶囊产业化项目,拟投入金额为 6268.00 万元,累计投入金额为 3092.79 万元,目前
已完成利用一期提取车间改造成中药精制车间工程和新建质检中心工程;利用一期综合制剂车间改造
成胶囊生产车间工程尚未开工,主要系为适应新版 GMP 标准对药品生产软、硬件条件要求的提高,正
在对原有车间设计方案进行调整,预计 2011 年底动工,2012 年完工。
    3、创新中药研究与(GLP)安全评价中心项目,拟投入金额为 8260.00 万元,累计投入金额为 3289.14
万元,已支付土地款,但由于当地政府对该项目地块周边范围规划调整,目前尚未获得土地权证和相
关施工许可证。
    3.2.2 非募集资金项目说明
             项目名称                     项目金额(万元)             项目进度
 行政办公楼                                             362.21                      15.41%
 培训中心                                               283.60                      14.18%
 中试研发平台                                          2727.78                      62.71%
 质检综合楼                                            1529.57                      54.55%
 北京研发总部装修                                       908.74                      83.37%
 上市品种再评价研发中心                                 175.44                       3.58%
 康缘弘道软胶囊生产线                                 10695.76                      22.28%
               合 计                                  16683.10              /


    3.2.3 重大合同履行情况
    2011 年 9 月 21 日,公司与江苏经略实业发展有限公司签署了《出资转让协议》,以 258 万元转
让公司持有的连云港康嘉国际贸易有限公司 86%的股权即 86 万元出资额。
    上述交易事项已经公司第四届董事会第十一次会议审议通过。2011 年 9 月 30 日,上述出资转让
的工商变更手续已完成。

    3.3 公司、股东及实际控制人承诺事项履行情况
    √适用 □不适用
    根据江苏康缘集团有限责任公司(简称“康缘集团”)在《股权分置改革方案》中的承诺,康缘
集团持有的康缘药业股份于 2008 年 11 月 16 日符合解禁条件,可以上市流通。2008 年 11 月 15 日,
康缘集团追加承诺:所持限售流通股自股改限售期满后三年内不上市流通。

    3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动
的警示及原因说明
    □ 适用 √不适用



    3.5 报告期内现金分红政策的执行情况
    本报告期内公司未进行现金分红。

                                                  5
江苏康缘药业股份有限公司(股票代码:600557)        2011 年第三季度报告



                                               江苏康缘药业股份有限公司
                                                        法定代表人:肖伟
                                                      2011 年 10 月 23 日




                                           6
      江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



§4 附录
4.1
                                  合并资产负债表(一)
                                         2011 年 9 月 30 日
编制单位: 江苏康缘药业股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
             项 目                              期末余额                    年初余额
流动资产:
    货币资金                                         154,274,288.63             151,523,396.75
    结算备付金
    拆出资金
    交易性金融资产                                     1,000,000.00
    应收票据                                         388,677,966.58             259,445,585.48
    应收账款                                         687,815,633.91             457,703,102.01
    预付款项                                         155,968,117.60             129,558,034.13
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利                                          3,607,284.00
    其他应收款                                       61,967,959.19               47,924,411.81
    买入返售金融资产
    存货                                             64,214,819.83               80,636,180.50
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                               1,517,526,069.74            1,126,790,710.68
非流动资产:
    持有至到期投资
    长期应收款
    长期股权投资                                      3,998,617.50
    投资性房地产
    固定资产                                         563,657,596.29             584,083,300.14
    在建工程                                         181,729,700.86              99,901,320.99
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                         112,281,323.26              94,352,106.33
    开发支出                                          20,600,000.00              20,600,000.00
    商誉                                              58,988,858.14              58,988,858.14
    长期待摊费用                                         112,954.28                 571,754.28
    递延所得税资产                                     2,650,582.71               2,193,145.57
    其他非流动资产
      非流动资产合计                               944,019,633.04              860,690,485.45
           资产总计                              2,461,545,702.78            1,987,481,196.13

公司法定代表人: 肖伟                主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉

                                                 7
     江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



                                 合并资产负债表(二)
                                        2011 年 9 月 30 日
编制单位: 江苏康缘药业股份有限公司
                                                     单位:元 币种:人民币 审计类型:未经审计
             项   目                           期末余额                    年初余额
流动负债:
    短期借款                                        505,000,000.00             310,089,895.30
    交易性金融负债
    应付票据                                         20,000,000.00              25,000,000.00
    应付账款                                        143,100,615.62             132,276,598.40
    预收款项                                         33,609,489.52              36,201,287.72
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                      5,403,125.91               5,644,058.53
    应交税费                                         42,451,572.19              28,849,214.47
    应付利息                                          1,165,850.66                 707,545.90
    应付股利                                          1,015,587.53
    其他应付款                                      118,270,163.86             117,037,070.55
    应付分保账款
    一年内到期的非流动负债
    其他流动负债                                     24,561,541.17              25,856,416.25
      流动负债合计                                  894,577,946.46             681,662,087.12
非流动负债:
    长期借款                                        118,000,000.00              58,000,000.00
    应付债券
    长期应付款
    专项应付款                                        3,391,085.00               3,525,285.00
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                              121,391,085.00                61,525,285.00
        负债合计                                1,015,969,031.46               743,187,372.12
所有者权益(或股东权益):
    实收资本(或股本)                              423,246,691.00             415,646,691.00
    资本公积                                        294,026,072.13             238,318,072.13
    减:库存股
    专项储备
    盈余公积                                        100,134,392.44             100,134,392.44
    一般风险准备
    未分配利润                                    592,261,262.72              455,654,287.57
    外币报表折算差额                                 -747,823.78                 -579,640.10
  归属于母公司所有者权益合计                    1,408,920,594.51            1,209,173,803.04
    少数股东权益                                   36,656,076.81               35,120,020.97
           所有者权益合计                       1,445,576,671.32            1,244,293,824.01
        负债和所有者权益总计                    2,461,545,702.78            1,987,481,196.13

公司法定代表人: 肖伟               主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉



                                                8
     江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



                                母公司资产负债表(一)
                                        2011 年 9 月 30 日
编制单位: 江苏康缘药业股份有限公司
                                                        单位:元 币种:人民币 审计类型:未经审计
             项   目                           期末余额                     年初余额
流动资产:
    货币资金                                        106,476,645.36             106,838,320.05
    交易性金融资产                                    1,000,000.00
    应收票据                                        334,176,273.70             224,091,682.55
    应收账款                                        595,509,814.22             358,664,162.46
    预付款项                                        136,483,276.28             118,034,244.42
    应收利息
    应收股利                                         3,607,284.00
    其他应收款                                      26,264,534.70               21,612,672.05
    存货                                            50,922,374.09               69,622,885.58
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                              1,254,440,202.35               898,863,967.11
非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                    190,874,813.17             167,736,195.67
    投资性房地产
    固定资产                                        528,461,924.40             548,271,370.83
    在建工程                                        115,201,547.84              63,163,381.26
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                        77,434,854.14               69,099,404.73
    开发支出                                        20,600,000.00               20,600,000.00
    商誉
    长期待摊费用
    递延所得税资产                                    1,242,250.89                  949,446.47
    其他非流动资产
      非流动资产合计                              933,815,390.44              869,819,798.96
         资产总计                               2,188,255,592.79            1,768,683,766.07

 公司法定代表人: 肖伟               主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉




                                                9
     江苏康缘药业股份有限公司(股票代码:600557)                         2011 年第三季度报告



                                母公司资产负债表(二)
                                        2011 年 9 月 30 日
编制单位: 江苏康缘药业股份有限公司
                                                        单位:元 币种:人民币 审计类型:未经审计
             项   目                           期末余额                     年初余额
流动负债:
    短期借款                                         400,000,000.00            247,000,000.00
    交易性金融负债
    应付票据                                          20,000,000.00             23,000,000.00
    应付账款                                         120,160,104.23            108,376,401.87
    预收款项                                          32,070,944.47             31,654,445.34
    应付职工薪酬                                       4,007,635.11              4,268,165.98
    应交税费                                          36,312,416.05             21,455,830.02
    应付利息                                             425,850.66                554,940.63
    应付股利
    其他应付款                                        95,846,247.23             93,799,585.33
    一年内到期的非流动负债
    其他流动负债                                      24,461,541.17             25,856,416.25
      流动负债合计                                   733,284,738.92            555,965,785.42
非流动负债:
    长期借款                                          48,000,000.00              8,000,000.00
    应付债券
    长期应付款
    专项应付款                                         3,391,085.00              3,525,285.00
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                                  51,391,085.00             11,525,285.00
        负债合计                                     784,675,823.92            567,491,070.42
所有者权益(或股东权益):
    实收资本(或股本)                               423,246,691.00            415,646,691.00
    资本公积                                         294,026,072.13            238,318,072.13
    减:库存股
    专项储备
    盈余公积                                          98,327,231.88             98,327,231.88
    一般风险准备
    未分配利润                                    587,979,773.86              448,900,700.64
所有者权益(或股东权益)合计                    1,403,579,768.87            1,201,192,695.65
负债和所有者权益总计                            2,188,255,592.79            1,768,683,766.07

 公司法定代表人: 肖伟               主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉




                                                10
         江苏康缘药业股份有限公司(股票代码:600557)                             2011 年第三季度报告



   4.2
                                             合并利润表
   编制单位: 江苏康缘药业股份有限公司
                                                            单位:元 币种:人民币 审计类型:未经审计

                                 本期金额            上期金额         年初至报告期期末   上年年初至报告期
          项目
                               (7-9 月)         (7-9 月)          金额(1-9 月)   期末金额(1-9 月)

一、营业总收入                421,861,306.87     325,424,903.75       1,158,410,142.14     950,533,512.96
     其中:营业收入           421,861,306.87     325,424,903.75       1,158,410,142.14     950,533,512.96
     利息收入
     已赚保费
     手续费及佣金收入
二、营业总成本                358,662,010.69     263,068,857.29        983,881,931.08      793,402,215.68
     其中:营业成本           105,005,515.65      85,163,454.05        329,167,481.16      254,694,748.80
     利息支出
     营业税金及附加             7,228,027.22       4,886,397.75          18,107,275.99      14,067,991.25
     销售费用                 176,336,155.47     128,341,931.21         457,865,766.75     378,127,351.29
     管理费用                  61,606,486.33      39,526,323.61         150,253,149.47     132,355,942.95
     财务费用                   7,723,880.63       5,115,442.27          25,799,153.34      11,545,546.29
     资产减值损失                 761,945.39          35,308.40           2,689,104.37       2,610,635.10
     投资收益(损失以“-”
                                  613,108.03            -256,415.43         618,264.36       1,231,741.53
号填列)
     其中:对联营企业和合
营企业的投资收益
三、营业利润(亏损以“-”
                               63,812,404.21      62,099,631.03         175,146,475.42     158,363,038.81
号填列)
     加:营业外收入            15,040,816.12            391,076.53       20,772,518.52       9,995,181.00
     减:营业外支出               232,612.04             22,404.12          296,167.36         116,505.29
   其中:非流动资产处置损

四、利润总额(亏损总额以
                               78,620,608.29      62,468,303.44        195,622,826.58      168,241,714.52
“-”号填列)
     减:所得税费用            11,949,128.67       9,272,833.73          29,586,837.18      23,515,930.90
五、净利润(净亏损以“-”
                               66,671,479.62      53,195,469.71        166,035,989.40      144,725,783.62
号填列)
     归属于母公司所有者的
                               66,038,320.38      52,012,147.88         162,753,751.62     143,373,288.95
净利润
     少数股东损益                 633,159.24       1,183,321.83           3,282,237.78       1,352,494.67
六、每股收益:
     (一)基本每股收益                  0.16                 0.12                0.39                  0.34
     (二)稀释每股收益                  0.16                 0.12                0.39                  0.34
七、其他综合收益
八、综合收益总额               66,671,479.62      53,195,469.71        166,035,989.40      144,725,783.62
     归属于母公司所有者的
                               66,038,320.38      52,012,147.88         162,753,751.62     143,373,288.95
综合收益总额
     归属于少数股东的综合
                                  633,159.24       1,183,321.83           3,282,237.78       1,352,494.67
收益总额

    公司法定代表人: 肖伟                主管会计工作负责人:陈友龙               会计机构负责人:焦晓杉

                                                    11
       江苏康缘药业股份有限公司(股票代码:600557)                          2011 年第三季度报告



                                         母公司利润表
 编制单位: 江苏康缘药业股份有限公司
                                                       单位:元 币种:人民币 审计类型:未经审计

                                本期金额           上期金额     年初至报告期期 上年年初至报告期
         项目
                              (7-9 月)        (7-9 月)    末金额(1-9 月) 期末金额(1-9 月)

一、营业收入               349,619,468.44      276,660,497.81   908,819,371.70     818,983,073.65
    减:营业成本            87,895,872.82       72,371,305.57   253,905,533.70     215,644,435.67
          营业税金及附加     6,019,498.28        4,324,017.93    14,524,066.55      12,527,525.81
          销售费用         136,754,902.56       99,623,107.98   338,441,564.81     302,888,089.03
          管理费用          50,428,162.87       34,980,845.95   114,128,899.14     120,860,662.13
          财务费用           6,402,309.97        4,704,193.28    21,479,164.12      10,948,668.44
          资产减值损失         779,227.38           26,633.94     2,037,644.29       1,518,670.45
         投资收益(损失以
                             5,320,645.17       -1,319,690.36     9,118,401.50          165,704.96
“-”号填列)
        其中:对联营企业
和合营企业的投资收益
二、营业利润(亏损以“-”
                            66,660,139.73       59,310,702.80   173,420,900.59     154,760,727.08
号填列)
    加:营业外收入          14,940,816.12         -208,266.35    18,489,310.82        9,330,845.25
    减:营业外支出             176,940.76           14,996.53       232,329.01           92,680.29
       其中:非流动资产处
置损失
三、利润总额(亏损总额以
                            81,424,015.09       59,087,439.92   191,677,882.40     163,998,892.04
“-”号填列)
    减:所得税费用          11,439,411.32        8,859,120.89    27,660,007.72       22,647,112.69
四、净利润(净亏损以“-”
                            69,984,603.77       50,228,319.03   164,017,874.68     141,351,779.35
号填列)
五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益
六、其他综合收益
七、综合收益总额            69,984,603.77       50,228,319.03   164,017,874.68     141,351,779.35

  公司法定代表人: 肖伟                主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉




                                                  12
      江苏康缘药业股份有限公司(股票代码:600557)                             2011 年第三季度报告



4.3
                                       合并现金流量表
                                          2011 年 1—9 月
编制单位: 江苏康缘药业股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
                                                      年初至报告期期末   上年年初至报告期期末
                      项目
                                                        金额(1-9 月)       金额(1-9 月)
一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                          969,681,808.85            965,680,342.99
    收到的税费返还                                          4,746,913.71              4,212,039.67
    收到其他与经营活动有关的现金                           64,596,078.80             27,793,467.61
      经营活动现金流入小计                              1,039,024,801.36            997,685,850.27
    购买商品、接受劳务支付的现金                          226,781,332.03            184,542,666.96
    支付给职工以及为职工支付的现金                        196,896,835.37            139,828,635.65
    支付的各项税费                                        205,424,210.08            155,333,247.97
    支付其他与经营活动有关的现金                          442,515,992.91            399,751,209.16
      经营活动现金流出小计                              1,071,618,370.39            879,455,759.74
         经营活动产生的现金流量净额                       -32,593,569.03            118,230,090.53
二、投资活动产生的现金流量:
    取得投资收益收到的现金
    处置固定资产、无形资产和其他长期资产收
                                                                338,053.05                86,469.36
回的现金净额
    处置子公司及其他营业单位收到的现金净额                   -1,567,042.64
    收到其他与投资活动有关的现金
      投资活动现金流入小计                                   -1,228,989.59                86,469.36
    购建固定资产、无形资产和其他长期资产支
                                                            237,154,436.54          254,714,014.84
付的现金
    投资支付的现金                                            5,000,000.00           46,688,215.50
    取得子公司及其他营业单位支付的现金净额                                           -9,633,827.96
    支付其他与投资活动有关的现金
      投资活动现金流出小计                                242,154,436.54            291,768,402.38
         投资活动产生的现金流量净额                      -243,383,426.13           -291,681,933.02
三、筹资活动产生的现金流量:
    吸收投资收到的现金                                       63,308,000.00
    取得借款收到的现金                                      502,722,872.50          361,996,358.00
    收到其他与筹资活动有关的现金                             18,019,804.11
      筹资活动现金流入小计                                  584,050,676.61          361,996,358.00
    偿还债务支付的现金                                      247,206,240.72          220,000,000.00
    分配股利、利润或偿付利息支付的现金                       39,385,503.91           41,870,688.97
    支付其他与筹资活动有关的现金                             18,600,000.00
      筹资活动现金流出小计                                  305,191,744.63          261,870,688.97
         筹资活动产生的现金流量净额                         278,858,931.98          100,125,669.03
四、汇率变动对现金及现金等价物的影响                           -131,044.94              -58,124.06
五、现金及现金等价物净增加额                                  2,750,891.88          -73,384,297.52
    加:期初现金及现金等价物余额                            151,523,396.75          236,228,252.54
六、期末现金及现金等价物余额                                154,274,288.63          162,843,955.02

 公司法定代表人: 肖伟                主管会计工作负责人:陈友龙               会计机构负责人:焦晓杉


                                                 13
      江苏康缘药业股份有限公司(股票代码:600557)                             2011 年第三季度报告



                                     母公司现金流量表
                                          2011 年 1—9 月
编制单位: 江苏康缘药业股份有限公司
                                                            单位:元 币种:人民币 审计类型:未经审计
                                                      年初至报告期期末金额 上年年初至报告期期末
                      项目
                                                            (1-9 月)          金额(1-9 月)
一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                            732,577,553.96          778,791,378.44
    收到的税费返还
    收到其他与经营活动有关的现金                             31,465,674.16           21,011,113.54
      经营活动现金流入小计                                  764,043,228.12          799,802,491.98
    购买商品、接受劳务支付的现金                            166,991,540.51           87,306,035.20
    支付给职工以及为职工支付的现金                          149,302,436.03          125,072,727.76
    支付的各项税费                                          165,856,727.63          139,473,829.77
    支付其他与经营活动有关的现金                            296,183,794.49          326,453,798.10
      经营活动现金流出小计                                  778,334,498.66          678,306,390.83
         经营活动产生的现金流量净额                         -14,291,270.54          121,496,101.15
二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                    3,792,500.00
    处置固定资产、无形资产和其他长期资产收
                                                                338,053.05                83,578.84
回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
      投资活动现金流入小计                                    4,130,553.05                83,578.84
    购建固定资产、无形资产和其他长期资产支
                                                            184,240,503.06          204,755,898.96
付的现金
    投资支付的现金                                           25,000,000.00           42,688,215.50
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
      投资活动现金流出小计                                  209,240,503.06          247,444,114.46
         投资活动产生的现金流量净额                        -205,109,950.01         -247,360,535.62
三、筹资活动产生的现金流量:
    吸收投资收到的现金                                       63,308,000.00
    取得借款收到的现金                                      384,000,000.00          310,000,000.00
    收到其他与筹资活动有关的现金
      筹资活动现金流入小计                                  447,308,000.00          310,000,000.00
    偿还债务支付的现金                                      191,000,000.00          220,000,000.00
    分配股利、利润或偿付利息支付的现金                       37,268,454.14           41,477,242.89
    支付其他与筹资活动有关的现金
      筹资活动现金流出小计                                  228,268,454.14          261,477,242.89
         筹资活动产生的现金流量净额                         219,039,545.86           48,522,757.11
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                                   -361,674.69          -77,341,677.36
    加:期初现金及现金等价物余额                            106,838,320.05          185,052,850.43
六、期末现金及现金等价物余额                                106,476,645.36          107,711,173.07

 公司法定代表人: 肖伟                主管会计工作负责人:陈友龙               会计机构负责人:焦晓杉


                                                 14